Navigation Links
Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
Date:9/17/2009

36.2% 13.6% 35.1% 26.3% 16.1% ---------------- ---- ---- ---- ---- ---- >/=10% weight loss (ITT-LOCF) 22.6% 7.7% 22.6% 17.4% 9.7% ---------------- ---- --- ---- ---- --- Mean weight loss (Per protocol) 8.2% 3.4% 7.9% 6.5% 3.9% ------------- --- --- --- --- --- Mean weight loss (ITT-LOCF) 5.8% 2.2% 5.9% 4.8% 2.8% --------- --- --- --- --- --- * p<0.0001 compared to placebo

"Lorcaserin demonstrated consistent results in the BLOOM and BLOSSOM trials, which together evaluated nearly 7,200 patients for up to two years," said William R. Shanahan, M.D., Arena's Vice President and Chief Medical Officer. "These results support lorcaserin's potential to meet the need for a safe, effective and well-tolerated weight loss medication. There are only two drugs that are approved by the FDA for long-term treatment, and new mechanistic and better tolerated approaches could greatly improve the treatment of patients who are obese or significantly overweight."

Safety and Tolerability Profile

Lorcaserin was very well tolerated. No adverse event rate in the lorcaserin group exceeded the placebo group by more than 4%. The most frequent adverse events and their rates for patients who took lorcaserin twice daily, lorcaserin once daily or placebo, respectively, were as follows: upper respiratory infection (12.7%, 14.5%, 12.6%); nasopharyngitis (12.5%, 11.7%, 11.8%) and headache (10.0%, 10.5%, 7.6%).

Adverse events of depression, anxiety and suicidal ideation were infrequent and were reported at a similar rate in each treatment group. Serious adverse events, or SAEs, occurred infrequently: one deat
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... FRANCISCO , July 1, 2015  goBalto, ... startup solutions, announced today unprecedented growth in serving ... is intense pressure to speed clinical trials and ... globalization, and paper-based methods have stalled these efforts," ... current status of clinical trials has encouraged Industry ...
(Date:7/1/2015)... Prismic Pharmaceuticals, Inc., a specialty pharmaceutical company ... announced the election of Joseph J. Krivulka ... of Directors. Commenting on the election of ... Chairman and CEO of Prismic, stated, "We are delighted ... have accepted our invitation to join Prismic,s Board ...
(Date:7/1/2015)... DIEGO , July 1, 2015  Imprimis ... company focused on the development and commercialization of ... company will ring The Nasdaq stock market closing ... celebrating the growing success of its Go Dropless™ ... 3.6 million cataract procedures are performed annually in ...
Breaking Medicine Technology:goBalto Triples Sites Managed, Further Reinforcing Market Leadership Position 2Joseph Krivulka and Martin Simonetti Join Board of Prismic Pharmaceuticals 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4
... 14 Medizone International, Inc. (OTC Bulletin ... AsepticSure(TM) trials have begun at Innovation Park, Queen,s University. ... and second round of laboratory testing, this third round ... in order to obtain maximum bactericidal action in combination ...
... , TROY, Mich., Oct. 14 Somanetics Corporation (Nasdaq: ... an Exclusive Sublicense Agreement with Raba Equity Partners II, ... Somanetics has obtained exclusive rights, subject to specified rights ... Johns Hopkins University, to new cerebral autoregulation technology developed ...
Cached Medicine Technology:Medizone International Announces Third Round of AsepticSure 2Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 2Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 3Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 4Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University 5
(Date:7/2/2015)... Beach, FL (PRWEB) , ... July 02, 2015 , ... ... information and entertainment differently, but also how they interact with products in their everyday ... everything from appliances and security systems to home entertainment and safety, as well as ...
(Date:7/2/2015)... ... ... an effect on the body. And during the hot summer season, fitness guru Iryna Lobur ... of the right foods, as well as drinking plenty of water. , But on the ... front as well, with sweet treats like ice cream and snow cones more popular than ever ...
(Date:7/2/2015)... ... July 02, 2015 , ... Patton State Hospital ... State Hospitals. Prior to using Winscribe’s dictation and clinical documentation solutions, Patton State ... manage their organization’s dictation and transcription processes. , Over the years, ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... their products, services, channels and business models. To help manage the increasing demand ... addition of Mark Benkendorf as SVP of Strategic Engagements. , Benkendorf is a ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... sponsorship complete, St. Joseph’s Health, located in Syracuse, N.Y., is now a member ... we have gained an admirable and important partner committed to delivering high-value care, ...
Breaking Medicine News(10 mins):Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 2Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 3Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 4Health News:Iryna Lobur Shares Healthy Treats to Eat for Summer 2Health News:Patton State Hospital Saves Over 50% and Removes Document Backlogs with Winscribe Text 2Health News:Patton State Hospital Saves Over 50% and Removes Document Backlogs with Winscribe Text 3Health News:Patton State Hospital Saves Over 50% and Removes Document Backlogs with Winscribe Text 4Health News:Business Builder Mark Benkendorf Joins Innovation Firm Maddock Douglas 2Health News:St. Joseph’s Health Now a Member of Trinity Health 2Health News:St. Joseph’s Health Now a Member of Trinity Health 3Health News:St. Joseph’s Health Now a Member of Trinity Health 4
... be pleased with a new study suggesting music lessons help ... at the Chinese University of Hong Kong, indicates children with ... without training. ,Researchers put 135 boys between ages 6 ... had to recall words from a list and perform a ...
... study shows anemia may double the risk of an ... the ability to live independently. Researchers say seniors who ... just above the traditional cut-off point for the condition's ... than those who have normal blood hemoglobin levels.// ...
... of intraocular fluid into the venous system, wearing a ... to a report published in the August issue of ... that wearing a tight necktie produces a significant rise ... Although it could take several years of tie wearing ...
... make people more susceptible to depression after stressful events, such ... have to inherit one copy of the gene, from either ... Britain, New Zealand and the United States found. ,Stress events, ... of the five leading causes of disability in the world. ...
... exams can make you break out. There are a lot ... clinical studies have looked at this, Dr. Alexa B. Kimball, ... study with the goal of debunking this myth," she added. ... clearly that acne causes stress," Kimball noted. But when she ...
... claim eating pizza regularly reduced the risk of developing throat ... also fell by 26 percent and mouth cancer by 34 ... developed cancer of the mouth, esophagus, throat or colon and ... Those who ate pizza at least once a week had ...
Cached Medicine News:
Designed to securely hold scleral plugs during insertion and removal. The cross action handle is designed to reduce hand fatigue while grasping plug....
Ergotec Vetriretinal Instrument System. Ultra-fine 3.35 mm jaws. Angled 55 degrees. 20 gauge shaft. 30 mm in length. Blackened tip. Overall length from rear rotation knob to tip....
Angled shafts with 12 mm scaled jaws. 1 mm teeth on one jaw fit into holes on the other jaw. Slide lock and serrated handle with polished finish. Left. Most popular size or model....
Shafts angled 45 degrees, 10 mm from tip to bend. 1 x 2 teeth. Serrated handle with polished finish. Most popular size or model....
Medicine Products: